Casuarinin effects on cancer chemoprevention: Progress, potential and promise

Authors

Jawaria Khan

Institute of Molecular Biology and Biotechnology, Bahauddin Zakarya University, Multan, Pakistan
Muhammad Imran Qadir

Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan
Muhammad Imran Qadir

Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan

DOI:

https://doi.org/10.7439/ijpr.v7i9.4352

Abstract

Casuarinin is tannin with many medicinal properties. It has antiproliferative, antioxidant, Anti herpes simplex virus (HSV) activity and anticancer activity. Anticancer activity of Casuarinin has been proven in breast cancer, non-small lung cancer, oral tumor and leukemia by different experiments. However further work is required to establish how this tannin system can be best manipulated for therapeutic benefit. This review focuses on the use of this tannin as a medicine for cancer treatment.

Downloads

Download data is not yet available.

References

. Health WHOR, Diseases WHOC, Promotion H. Comprehensive cervical cancer control: a guide to essential practice: World Health Organization; 2006.

. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA: A Cancer Journal for Clinicians. 2005; 55(1):10-30.

. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). International Journal of Oncology. 2007; 30(1): 233-46.

. Howlader N, Noone A-M, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD. 2013.

. Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. The Lancet Haematology. 2015; 2(5):e186-e93.

. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA: A Cancer Journal for Clinicians. 2016; 66(6):443-59.

. Team NLSTR. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 2011(365):395-409.

. Rose VPD, White MC, Klabunde C, Nadel M, Richards TB, McNeel TS, et al. Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. Cancer Epidemiology and Prevention Biomarkers. 2012: cebp. 0343.2012.

. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. Journal of Nuclear Medicine. 2005; 46(1 suppl):141S-50S.

. Antonia S, Mulé JJ, Weber JS. Current developments of immunotherapy in the clinic. Current opinion in immunology. 2004; 16(2):130-6.

. Caponigro F, Basile M, de Rosa V, Normanno N. New drugs in cancer therapy, National Tumor Institute, Naples, 17–18 June 2004. LWW; 2005.

. Miner TJ. Palliative surgery for advanced cancer: lessons learned in patient selection and outcome assessment. American Journal of Clinical Oncology. 2005; 28(4):411-4.

. Smith JJ, Tully P, Padberg RM, editors. Chemoprevention: a primary cancer prevention strategy. Seminars in oncology nursing; 2005: Elsevier.

. Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nature Clinical Practice Oncology. 2005; 2(10):518-25.

. Shukla S, Gupta S. Dietary agents in the chemoprevention of prostate cancer. Nutrition and cancer. 2005; 53(1):18-32.

. Kim ES, Hong WK. An apple a day… does it really keep the doctor away? The current state of cancer chemoprevention. Oxford University Press; 2005.

. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacology & Therapeutics. 2001; 90(2):157-77.

. Genkinger JM, Platz EA, Hoffman SC, Comstock GW, Helzlsouer

KJ. Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. American Journal of Epidemiology. 2004; 160(12):1223-33.

. Crowell JA. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview. European Journal of Cancer. 2005; 41(13):1889-910.

. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians. 2017; 67(1):7-30.

. Decker EA. The role of phenolics, conjugated linoleic acid, carnosine, and pyrroloquinoline quinone as nonessential dietary antioxidants. Nutrition Reviews. 1995; 53(3):49-58.

. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods in enzymology. 1994; 234:279-93.

. Kadam S, Salunkhe D, Chavan J. Dietary tannins: consequences and remedies. Boca Raton: CRC Press; 1990.

. Foo LY, Porter LJ. The structure of tannins of some edible fruits. Journal of the Science of Food and Agriculture. 1981; 32(7):711-6.

. Haslam E, Lilley T, Cai Y, Martin R, Mangnolato D. Traditional herbal medicines-the role of polyphenols. Planta Medica. 1989; 55(01):1-8.

. Pierpoint W. Flavonoids in human food and animal feedstuffs: amounts and consequences. Flavonoids in biology and medicine III Current issues in flavonoids research. 1990.

. Hagerman AE, Zhao Y, Johnson S. Methods for determination of condensed and hydrolyzable tannins. ACS Publications; 1997.

. Kaur C, Kapoor HC. Antioxidants in fruits and vegetables–the millennium’s health. International Journal of Food Science & Technology. 2001; 36(7):703-25.

. Ito H, Miyake M, Nishitani E, Mori K, Hatano T, Okuda T, et al. Anti-tumor promoting activity of polyphenols from Cowania mexicana and Coleogyne ramosissima. Cancer letters. 1999; 143(1):5-13.

. Shalini S, Kumar RR, Birendra S. Terminalia Arjuna bark on Human Breast Cancer Cell Lines (MCF-7). Int J Drug Dev & Res. 2015; 7(1):0975-9344.

. Sakagami H, Jiang Y, Kusama K, Atsumi T, Ueha T, Toguchi M, et al. Cytotoxic activity of hydrolyzable tannins against human oral tumor cell lines—a possible mechanism. Phytomedicine. 2000; 7(1):39-47.

. Kwon D-J, Bae Y-S, Ju SM, Goh AR, Youn GS, Choi SY, et al. Casuarinin suppresses TARC/CCL17 and MDC/CCL22 production via blockade of NF-κB and STAT1 activation in HaCaT cells. Biochemical and biophysical research communications. 2012; 417(4):1254-9.

Published

2017-10-07

How to Cite

Khan J, Qadir MI, Qadir MI. . Int J of Pharmc Res [Internet]. 2017Oct.7 [cited 2020Jun.2];7(9):175-80. Available from: https://ssjournals.net/index.php/ijpr/article/view/4352

Issue

Vol. 7 No. 9 (2017): Sep

Section

Review Article

Authors who publish with this journal agree to the following terms:

1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
4. Author must Submit Copyright form After acceptance of Article